Scientist Off-Target Screening and Characterization*
- Characterization and direct identification of the recognized peptide space of T cell receptors (TCRs) or monoclonal antibodies (mAbs) directed against peptide:MHC targets employing state of the art mass spectrometry techniques.
- In silico analyses and risk assessment of off-target peptides utilizing Immatics’ unique XPRESIDENT® platform. Advancement of prediction tools by integration of data from different ‘-omics’ approaches (e.g., transcriptomics, proteomics, immunopeptidomics).
- Independent coordination of your work in close interaction with a team of scientific experts from various departments. This includes communication and presentation in internal meetings and towards external partners.
This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.